AI could help spot eye disease in kids with diabetes
NCT ID NCT07149142
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will test whether artificial intelligence (AI) can effectively screen for diabetic retinopathy (eye damage) in 400 children with type 1 diabetes. Each child will have their eyes examined using an AI-powered camera, standard eye exams, and a detailed scan. The researchers will compare the AI results to the standard methods to see if AI is a reliable, easy-to-use screening tool. They will also look at how common eye problems are in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Artificial intelligence software for diabetic retinopathy screening
What this could lead to
If successful, this could make eye screening faster and easier for children with diabetes, potentially catching problems earlier.
What could go wrong
This is a small, early feasibility study at one center. The AI may not be as accurate as standard exams, and results may not apply to all children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Motol
Prague, Prague 5, 15006, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••